|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/18/21 Syneos Health, Inc. 10-K 12/31/20 130:23M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.16M
2: EX-10.16 Ex-10.16.2 First Amendment to the Purchase and HTML 68K
Sale Agreement
3: EX-10.16 Ex-10.16.5 Fifth Amendment Purchase and Sale HTML 100K
Agreement
4: EX-10.17 Ex-10.17.11 Tenth Amendment Receivables Financing HTML 237K
Agreement
5: EX-21.1 EX-21.1 Subsidiaries of the Registrant HTML 84K
6: EX-23.1 EX-23.1 Consent of Deloitte & Touche LLP HTML 34K
7: EX-31.1 EX-31.1 Section 302 CEO Certification HTML 38K
8: EX-31.2 EX-31.2 Section 302 CFO Certification HTML 38K
9: EX-32.1 EX-32.1 Section 906 CEO Certification HTML 37K
10: EX-32.2 EX-32.2 Section 906 CFO Certification HTML 37K
17: R1 Cover Page HTML 99K
18: R2 Consolidated Statements of Income HTML 112K
19: R3 Consolidated Statements of Comprehensive Income HTML 52K
(Loss)
20: R4 Consolidated Statements of Comprehensive Income HTML 40K
(Loss) (Parenthetical)
21: R5 Consolidated Balance Sheets HTML 132K
22: R6 Consolidated Balance Sheets (Parenthetical) HTML 52K
23: R7 Consolidated Statements of Cash Flows HTML 136K
24: R8 Consolidated Statements of Shareholders' Equity HTML 84K
25: R9 Basis of Presentation and Summary of Significant HTML 129K
Accounting Policies
26: R10 Financial Statement Details HTML 498K
27: R11 Business Combinations and Divestitures HTML 89K
28: R12 Long-Term Debt Obligations HTML 127K
29: R13 Leases HTML 218K
30: R14 Derivatives HTML 71K
31: R15 Fair Value Measurements HTML 255K
32: R16 Restructuring and Other Costs HTML 150K
33: R17 Shareholders' Equity HTML 159K
34: R18 Earnings Per Share HTML 93K
35: R19 Income Taxes HTML 376K
36: R20 Revenue from Contracts with Customers HTML 42K
37: R21 Segment Information HTML 165K
38: R22 Operations by Geographic Location HTML 98K
39: R23 Concentration of Credit Risk HTML 39K
40: R24 Related-Party Transactions HTML 40K
41: R25 Commitments and Contingencies HTML 45K
42: R26 Share-Based Compensation HTML 156K
43: R27 Employee Benefit Plans HTML 54K
44: R28 Basis of Presentation and Summary of Significant HTML 187K
Accounting Policies (Policies)
45: R29 Basis of Presentation and Summary of Significant HTML 111K
Accounting Policies (Tables)
46: R30 Financial Statement Details (Tables) HTML 586K
47: R31 Business Combinations and Divestitures (Tables) HTML 84K
48: R32 Long-Term Debt Obligations (Tables) HTML 113K
49: R33 Leases (Tables) HTML 277K
50: R34 Derivatives (Tables) HTML 66K
51: R35 Fair Value Measurements (Tables) HTML 255K
52: R36 Restructuring and Other Costs (Tables) HTML 147K
53: R37 Shareholders' Equity (Tables) HTML 160K
54: R38 Earnings Per Share (Tables) HTML 91K
55: R39 Income Taxes (Tables) HTML 370K
56: R40 Segment Information (Tables) HTML 159K
57: R41 Operations by Geographic Location (Tables) HTML 101K
58: R42 Share-Based Compensation (Tables) HTML 156K
59: R43 Employee Benefit Plans (Tables) HTML 47K
60: R44 Basis of Presentation and Summary of Significant HTML 92K
Accounting Policies - Narrative (Details)
61: R45 Basis of Presentation and Summary of Significant HTML 40K
Accounting Policies - Net Cash Pool Position
(Details)
62: R46 Basis of Presentation and Summary of Significant HTML 50K
Accounting Policies - Estimated Useful Lives of
Property and Equipment (Details)
63: R47 Basis of Presentation and Summary of Significant HTML 46K
Accounting Policies - Estimated Useful Lives of
Intangible Assets (Details)
64: R48 Financial Statement Details - Accounts Receivable HTML 55K
and Unbilled Services, net (Details)
65: R49 Financial Statement Details - Narrative (Details) HTML 50K
66: R50 Financial Statement Details - Schedule of Property HTML 58K
and Equipment, Net (Details)
67: R51 Financial Statement Details - Schedule of Goodwill HTML 57K
(Details)
68: R52 Financial Statement Details - Schedule of HTML 53K
Intangible Assets (Details)
69: R53 Financial Statement Details - Schedule of Future HTML 51K
Amortization Expense (Details)
70: R54 Financial Statement Details - Schedule of Accrued HTML 57K
Expenses (Details)
71: R55 Financial Statement Details - Accumulated Other HTML 54K
Comprehensive Loss, Net of Taxes (Details)
72: R56 Financial Statement Details - Tax Effects HTML 59K
Allocated to Each Component of Other Comprehensive
(Loss) Income (Details)
73: R57 Financial Statement Details - Transaction and HTML 46K
Integration-Related Expenses (Details)
74: R58 Financial Statement Details - Schedule of Other HTML 48K
(Income) Expense, Net (Details)
75: R59 Financial Statement Details - Supplemental Cash HTML 52K
Flow Information (Details)
76: R60 Business Combinations and Divestitures - Narrative HTML 92K
(Details)
77: R61 Business Combinations and Divestitures - HTML 78K
Allocation of Consideration Transferred (Details)
78: R62 Business Combinations and Divestitures - HTML 47K
Preliminary Estimates of Fair Value of Intangible
Assets and Estimated Useful Lives (Details)
79: R63 Long-Term Debt Obligations - Schedule of Debt HTML 65K
Obligations (Details)
80: R64 Long-Term Debt Obligations - Narrative (Details) HTML 126K
81: R65 Long-Term Debt Obligations - Schedule of Variable HTML 58K
Rate Margins (Details)
82: R66 Long-Term Debt Obligations - Accounts Receivable HTML 67K
Financing Agreement (Details)
83: R67 Long-Term Debt Obligations - Contractual HTML 59K
Maturities of Debt Obligations (Details)
84: R68 Leases - Narrative (Details) HTML 42K
85: R69 Leases - Components of Lease Cost (Details) HTML 51K
86: R70 Leases - Supplemental Balance Sheet Information HTML 48K
Related to Leases (Details)
87: R71 Leases - Supplemental Cash Flow Information HTML 48K
Related to Leases (Details)
88: R72 Leases - Supplemental Cash Flow Information, HTML 44K
Weighted Average (Details)
89: R73 Leases - Maturities of Lease Liabilities (Details) HTML 88K
90: R74 Derivatives - Narrative (Details) HTML 60K
91: R75 Derivatives - Interest Rate Swaps Designated as HTML 53K
Hedging Instruments on Consolidated Balance Sheets
(Details)
92: R76 Fair Value Measurements - Schedule of Assets and HTML 68K
Liabilities Measured at Fair Value on a Recurring
Basis (Details)
93: R77 Fair Value Measurements - Schedule of Assets and HTML 44K
Liabilities Measured at Fair Value on a Recurring
Basis (Parenthetical) (Details)
94: R78 Fair Value Measurements - Reconciliation of HTML 42K
Changes in the Carrying Amount of Contingent
Consideration (Details)
95: R79 Fair Value Measurements - Narrative (Details) HTML 57K
96: R80 Fair Value Measurements - Schedule of Estimated HTML 55K
Fair Value (Details)
97: R81 Restructuring and Other Costs - Merger Related HTML 51K
Restructuring (Details)
98: R82 Restructuring and Other Costs - Non-Merger Related HTML 45K
Restructuring and Other Costs (Details)
99: R83 Restructuring and Other Costs - Schedule of HTML 62K
Restructuring and Related Costs (Details) -
Business Restructuring Reserves
100: R84 Shareholders' Equity - Shares of Common Stock HTML 43K
Outstanding (Details)
101: R85 Shareholders' Equity - Narrative (Details) HTML 58K
102: R86 Shareholders' Equity - Repurchase Activity HTML 45K
(Details)
103: R87 Shareholders' Equity - Schedule of Stock by Class HTML 58K
(Details)
104: R88 Earnings Per Share - Schedule of Earnings Per HTML 69K
Share, Basic and Diluted (Details)
105: R89 Earnings Per Share - Narrative (Details) HTML 37K
106: R90 Income Taxes - Components of Income before HTML 45K
Provision for Income Taxes (Details)
107: R91 Income Taxes - Schedule of Components of Income HTML 58K
Tax Expense (Benefit) (Details)
108: R92 Income Taxes - Narrative (Details) HTML 79K
109: R93 Income Taxes - Schedule of Effective Income Tax HTML 81K
Rate Reconciliation (Details)
110: R94 Income Taxes - Summary of Valuation Allowance HTML 51K
(Details)
111: R95 Income Taxes - Schedule of Deferred Tax Assets and HTML 81K
Liabilities (Details)
112: R96 Income Taxes - Schedule of Unrecognized Tax HTML 51K
Benefits (Details)
113: R97 Revenue from Contracts with Customers - Narrative HTML 47K
(Details)
114: R98 Segment Information (Details) HTML 79K
115: R99 Operations by Geographic Location - Total Revenue HTML 58K
by Geographic Area (Details)
116: R100 Operations by Geographic Location - Long-Lived HTML 48K
Assets by Geographic Area (Details)
117: R101 Concentration of Credit Risk - Narrative (Details) HTML 43K
118: R102 Related-Party Transactions - Narrative (Details) HTML 53K
119: R103 Commitments and Contingencies - Narrative HTML 51K
(Details)
120: R104 Share-Based Compensation - Narrative (Details) HTML 85K
121: R105 Share-Based Compensation - Stock Option Valuation HTML 48K
Assumptions (Details)
122: R106 Share-Based Compensation - Summary of Option HTML 86K
Activity (Details)
123: R107 Share-Based Compensation - Summary of Restricted HTML 58K
Stock Unit Activity (Details)
124: R108 Share-Based Compensation - Summary of Share-Based HTML 45K
Compensation Expense (Details)
125: R109 Employee Benefit Plans - Schedule of Contributions HTML 37K
to Defined Contribution Plan (Details)
126: R110 Employee Benefit Plans - Narrative (Details) HTML 49K
128: XML IDEA XML File -- Filing Summary XML 244K
16: XML XBRL Instance -- synh-10k_20201231_htm XML 6.10M
127: EXCEL IDEA Workbook of Financial Reports XLSX 175K
12: EX-101.CAL XBRL Calculations -- synh-20201231_cal XML 372K
13: EX-101.DEF XBRL Definitions -- synh-20201231_def XML 1.05M
14: EX-101.LAB XBRL Labels -- synh-20201231_lab XML 2.16M
15: EX-101.PRE XBRL Presentations -- synh-20201231_pre XML 1.77M
11: EX-101.SCH XBRL Schema -- synh-20201231 XSD 276K
129: JSON XBRL Instance as JSON Data -- MetaLinks 635± 1.01M
130: ZIP XBRL Zipped Folder -- 0001564590-21-006471-xbrl Zip 652K
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Alistair Macdonald, Chief Executive Officer of Syneos Health, Inc. (the “registrant”), do hereby certify, that to the best of my knowledge:
1. The registrant's Annual Report on Form 10-K for the period ended December 31, 2020, (the “Report”), to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 17, 2021
|
|
|
|
|
Chief Executive Officer |
||
|
(Principal Executive Officer) |
||
This certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of the Report, irrespective of any general incorporation language contained in such filing.
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 2/18/21 | 4, 8-K | ||
| Filed on: | 2/17/21 | 8-K | ||
| For Period end: | 12/31/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/16/23 Syneos Health, Inc. 10-K 12/31/22 136:28M Donnelley … Solutions/FA 2/17/22 Syneos Health, Inc. 10-K 12/31/21 134:25M ActiveDisclosure/FA 6/04/21 Syneos Health, Inc. 424B7 1:390K Donnelley … Solutions/FA 5/05/21 Syneos Health, Inc. 424B7 1:398K Donnelley … Solutions/FA 4/29/21 Syneos Health, Inc. 10-Q 3/31/21 84:9M ActiveDisclosure/FA 3/03/21 Syneos Health, Inc. 424B7 1:405K Donnelley … Solutions/FA |